{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:31:28Z","timestamp":1791012688774,"version":"4.1.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Innovations in both the surgical and medical management of breast cancer over the past few decades have led to reductions in treatment-related morbidity and increases in overall survival. Despite these advancements in traditional therapies, including surgery, chemotherapy, radiation, endocrine therapy, and immunotherapy, a subset of patients continues to choose complementary and alternative medicine (CAM).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe the association of CAM with survival in patients with breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study analyzed data from the National Cancer Database on female patients diagnosed with breast cancer from 2011 through 2021. Survival time was compared among patients who received traditional treatment, traditional treatment and CAM, and no treatment. Data were analyzed from May 2025 to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Complementary or alternative treatment, defined in the NCDB as treatment administered by nonmedical personnel.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was 5-year survival. Unadjusted 5-year survival was assessed by Kaplan-Meier analysis, and adjusted survival was assessed with a Cox proportional hazards model controlled for age, race and ethnicity, Charlson Comorbidity index, insurance type, facility type, region, year of diagnosis, cancer stage, and income.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 2\u202f169\u202f202 female patients with breast cancer identified, 2\u202f157\u202f219 (median [IQR] age, 62 [52-71] years) were included in the sample. A total of 2 106 665 patients (97.6%) received traditional therapy, 273 (&amp;lt;0.1%) received CAM alone, 568 (&amp;lt;0.1%) received a combination of CAM and traditional therapies, and 49 713 (2.3%) received no treatment. Compared with patients treated with traditional therapies, those treated with CAM alone (adjusted hazard ratio [AHR], 3.67; 95% CI, 3.03-4.44;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) or no treatment (AHR, 3.53; 95% CI, 3.48-3.58;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) had the highest risks for mortality. Patients who received a combination of traditional therapies and CAM were less likely to receive endocrine therapy (eg, 40.7% vs 65.2% in stage II;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and radiation (59.5% vs 36.6% in stage II;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) compared with patients treated exclusively with traditional therapies. Receipt of a combination of traditional therapies and CAM was associated with a higher mortality compared with being treated exclusively with traditional therapy (AHR, 1.45; 95% CI, 1.22-1.72;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of data from female patients with breast cancer included in the NCDB, the use of CAM instead of traditional therapies was uncommon but was associated with a reduction in survival time. Further study is warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0337","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:00:27Z","timestamp":1772467227000},"page":"e260337","source":"Crossref","is-referenced-by-count":8,"title":["Use of Complementary and Alternative Medicine in the Management of Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Oluwaseun F.","family":"Ayoade","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Caturegli","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen E.","family":"Canavan","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Resio","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Berger","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Boffa","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Yale Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"6","key":"zoi260027r1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022.","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi260027r2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024.","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"zoi260027r3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023714","article-title":"Look how far we have come: breast cancer detection education on the international stage.","volume":"12","author":"Trieu","year":"2023","journal-title":"Front Oncol"},{"key":"zoi260027r4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer.","volume":"8","author":"Tong","year":"2018","journal-title":"Front Oncol"},{"issue":"6","key":"zoi260027r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005285","article-title":"A hard pill to swallow: a qualitative study of women\u2019s experiences of adjuvant endocrine therapy for breast cancer.","volume":"4","author":"Harrow","year":"2014","journal-title":"BMJ Open"},{"issue":"9869","key":"zoi260027r6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"17","key":"zoi260027r7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"zoi260027r8","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199906033402206","article-title":"Use of alternative medicine by women with early-stage breast cancer.","volume":"340","author":"Burstein","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260027r9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2019.0349","article-title":"Prevalence and nondisclosure of complementary and alternative medicine use in patients with cancer and cancer survivors in the United States.","volume":"5","author":"Sanford","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi260027r10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1534735416668575","article-title":"Interest in integrative medicine among postmenopausal hormone receptor-positive breast cancer patients in the EVALUATE-TM study.","volume":"16","author":"Hack","year":"2017","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"zoi260027r11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S1478951503030256","article-title":"Complementary and alternative medicine in breast cancer patients.","volume":"1","author":"Nahleh","year":"2003","journal-title":"Palliat Support Care"},{"issue":"1","key":"zoi260027r12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11764-010-0153-7","article-title":"Complementary and alternative medicine use among cancer survivors: a population-based study.","volume":"5","author":"Mao","year":"2011","journal-title":"J Cancer Surviv"},{"issue":"13","key":"zoi260027r13","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2000.18.13.2505","article-title":"Complementary\/alternative medicine use in a comprehensive cancer center and the implications for oncology.","volume":"18","author":"Richardson","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260027r14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/107555302760253676","article-title":"Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs.","volume":"8","author":"Patterson","year":"2002","journal-title":"J Altern Complement Med"},{"issue":"3","key":"zoi260027r15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/2374373517706612","article-title":"Prevalence and predictors of herbal medicine use among adults in the United States.","volume":"4","author":"Rashrash","year":"2017","journal-title":"J Patient Exp"},{"issue":"2","key":"zoi260027r16","doi-asserted-by":"publisher","DOI":"10.2196\/34183","article-title":"Timing and motivations for alternative cancer therapy with insights from a crowdfunding platform: cross-sectional mixed methods study.","volume":"8","author":"Peterson","year":"2022","journal-title":"JMIR Cancer"},{"issue":"1","key":"zoi260027r17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1353\/hpu.2011.0002","article-title":"Trends in the use of complementary and alternative medicine in the United States: 2002-2007.","volume":"22","author":"Su","year":"2011","journal-title":"J Health Care Poor Underserved"},{"key":"zoi260027r18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fpubh.2017.00056","article-title":"Comparing complementary and alternative medicine use with or without including prayer as a modality in a local and diverse United States jurisdiction.","volume":"5","author":"Robles","year":"2017","journal-title":"Front Public Health"},{"issue":"12","key":"zoi260027r19","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review.","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260027r21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41598-023-27578-4","article-title":"Racial disparities in breast cancer treatment patterns and treatment related adverse events.","volume":"13","author":"Stabellini","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"zoi260027r22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/jamaoncol.2025.0247","article-title":"Smoking status of the US cancer population and a new perspective from the National Cancer Database.","volume":"11","author":"Caturegli","year":"2025","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260027r24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx145","article-title":"Use of alternative medicine for cancer and its impact on survival.","volume":"110","author":"Johnson","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"zoi260027r25","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.23.02311","article-title":"Racial differences in breast cancer survival between black and white women according to tumor subtype: a systematic review and meta-analysis.","volume":"42","author":"Torres","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260027r26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamaoncol.2021.7656","article-title":"Assessment of racial disparity in survival outcomes for early hormone receptor-positive breast cancer after adjusting for insurance status and neighborhood deprivation: a post hoc analysis of a randomized clinical trial.","volume":"8","author":"Sadigh","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260027r27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/whr.2021.0082","article-title":"Rural-urban differences in breast cancer stage at diagnosis.","volume":"3","author":"LeBlanc","year":"2022","journal-title":"Womens Health Rep (New Rochelle)"},{"issue":"12","key":"zoi260027r28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/jech-2019-212425","article-title":"Geographic disparities in cancer screening and fatalism among a nationally representative sample of US adults.","volume":"73","author":"Moss","year":"2019","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"zoi260027r29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/SLA.0000000000002095","article-title":"The effect of hospital volume on breast cancer mortality.","volume":"267","author":"Greenup","year":"2018","journal-title":"Ann Surg"},{"issue":"3","key":"zoi260027r30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2105\/AJPH.88.3.454","article-title":"Hospital volume differences and five-year survival from breast cancer.","volume":"88","author":"Roohan","year":"1998","journal-title":"Am J Public Health"},{"issue":"16","key":"zoi260027r31","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1002\/cncr.30722","article-title":"Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.","volume":"123","author":"Hsu","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"zoi260027r32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/cncr.33330","article-title":"Relationship between insurance status and outcomes for patients with breast cancer in Missouri.","volume":"127","author":"Berrian","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"zoi260027r33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-20-3974","article-title":"Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women.","volume":"27","author":"Collin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi260027r34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","article-title":"Adherence to tamoxifen over the five-year course.","volume":"99","author":"Lash","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"zoi260027r35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pec.2004.10.005","article-title":"Adherence beliefs among breast cancer patients taking tamoxifen.","volume":"59","author":"Grunfeld","year":"2005","journal-title":"Patient Educ Couns"},{"issue":"9","key":"zoi260027r36","doi-asserted-by":"publisher","first-page":"e1417","DOI":"10.1200\/OP.21.00719","article-title":"Geographical disparities and factors associated with the decision to decline chemotherapy in breast cancer.","volume":"18","author":"Jabbal","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"16","key":"zoi260027r37","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.2022.40.16_suppl.520","article-title":"Chemotherapy refusal and subsequent survival in older women with high genomic risk, estrogen receptor\u2013positive breast cancer.","volume":"40","author":"White","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260027r38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13014-023-02297-2","article-title":"Radiotherapy refusal in breast cancer with breast-conserving surgery.","volume":"18","author":"Liu","year":"2023","journal-title":"Radiat Oncol"},{"issue":"5","key":"zoi260027r39","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1634\/theoncologist.2012-0436","article-title":"Refusing treatment.","volume":"18","author":"Frenkel","year":"2013","journal-title":"Oncologist"},{"issue":"5","key":"zoi260027r40","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1634\/theoncologist.2011-0468","article-title":"Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapies.","volume":"17","author":"Citrin","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"zoi260027r41","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.21037\/gs-23-154","article-title":"Radiation and free flaps: what is the optimal timing?","volume":"12","author":"Koesters","year":"2023","journal-title":"Gland Surg"},{"issue":"9","key":"zoi260027r42","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1470-2045(24)00347-4","article-title":"Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.","volume":"25","author":"Williams","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi260027r43","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.3390\/cancers15164190","article-title":"Extended adjuvant endocrine therapy in early breast cancer patients-review and perspectives.","volume":"15","author":"Bekes","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"18","key":"zoi260027r44","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.3390\/cancers15184513","article-title":"The effects of complementary therapies on patient-reported outcomes: an overview of recent systematic reviews in oncology.","volume":"15","author":"Mentink","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"52","key":"zoi260027r45","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgx005","article-title":"The National Cancer Institute\u2019s conference on acupuncture for symptom management in oncology: state of the science, evidence, and research gaps.","volume":"2017","author":"Zia","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"3","key":"zoi260027r46","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1200\/JOP.2016.015081","article-title":"Integrating oncology massage into chemoinfusion suites: a program evaluation.","volume":"13","author":"Mao","year":"2017","journal-title":"J Oncol Pract"},{"issue":"3","key":"zoi260027r47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jpainsymman.2003.12.016","article-title":"Massage therapy for symptom control: outcome study at a major cancer center.","volume":"28","author":"Cassileth","year":"2004","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"zoi260027r48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3109\/0284186X.2012.745948","article-title":"Effect of mindfulness-based stress reduction on sleep quality: results of a randomized trial among Danish breast cancer patients.","volume":"52","author":"Andersen","year":"2013","journal-title":"Acta Oncol"},{"issue":"1","key":"zoi260027r49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-011-1738-1","article-title":"The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial.","volume":"131","author":"Henderson","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi260027r50","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_431554","article-title":"Integrative therapies in cancer care: an update on the guidelines.","volume":"44","author":"Gowin","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"zoi260027r51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JOP.18.00554","article-title":"Putting integrative oncology into practice: concepts and approaches.","volume":"15","author":"Latte-Naor","year":"2019","journal-title":"J Oncol Pract"},{"key":"zoi260027r52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.breast.2016.04.012","article-title":"Complementary and integrative medicine for breast cancer patients\u2014evidence based practical recommendations.","volume":"28","author":"Witt","year":"2016","journal-title":"Breast"},{"key":"zoi260027r20","unstructured":"American College of Surgeons. About the National Cancer Database. Accessed September 20, 2023. https:\/\/www.facs.org\/quality-programs\/cancer\/ncdb\/about"},{"key":"zoi260027r23","unstructured":"National Cancer Database Participant User File 2022 Data Dictionary. American College of Surgeons. July 2024. Accessed January 12, 2025. https:\/\/www.facs.org\/media\/fowa425u\/2022-data-dictionary.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2845669\/ayoade_2026_oi_260027_1772226444.75105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:00:28Z","timestamp":1772467228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2845669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0337","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}